Bowen Acquisition Corp has announced a significant update to its merger plans involving Shenzhen Qianzhi BioTechnology Co. Ltd. The company has entered into a second amendment to the Agreement and Plan of Reorganization, originally dated January 18, 2024, and previously amended on March 21, 2025. This latest amendment extends the deadline for completing the merger to December 14, 2025. The transaction involves Bowen Merger Sub merging with Qianzhi Group Holding (Cayman) Limited, with the latter becoming a wholly owned subsidiary of Bowen Acquisition Corp.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bowen Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-016871), on June 27, 2025, and is solely responsible for the information contained therein.